Cancer Certa Therapeutics patents new GPR68 antagonists Aug. 22, 2025 Certa Therapeutics Pty Ltd. has disclosed ovarian cancer G-protein coupled receptor 1 (GPR68; OGR1) antagonists reported to be useful for the treatment of cancer, inflammation and fibrosis.Read More